Related Experiment Video
Updated: Feb 13, 2026

Duodenal-Jejunal Bypass Surgery in Diet-Induced Obese Diabetic Mice
Published on: October 18, 2024
[EndoBarrier as a treatment for obesity and diabetes]
1Zuyderland Medisch Centrum, afd. Chirurgie, Heerlen.
Abstract:
The EndoBarrier (duodenal-jejunal bypass liner) became available in 2009 as an endoscopic treatment method for obesity and type 2 diabetes mellitus (T2D). The treatment results in significant weight loss and improvement of the obesity-related morbidities such as T2D, non-alcoholic steatohepatitis, hypertension and other cardiovascular diseases. However, unexpected complications such as liver abscesses can occur, in addition to expected adverse events such as bleeding, obstruction, and migration. The incidence of these complications is low however, and to date no treatment-related mortality has occurred with the use of EndoBarrier. After more than 3800 procedures, it can be concluded that the EndoBarrier is safe and effective. This treatment option can be applied in patients with a BMI over 30 kg/m2 and also obese patients with T2D who do not wish to undergo, or are not fit for, a surgical procedure.
Related Concept Videos
Obesity
Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Drug Dosing: Obese Patients
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Psychoneuroimmunology: Diabetes and Cancer
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

![Assessment of Gastric Emptying in Non-obese Diabetic Mice Using a [13C]-octanoic Acid Breath Test](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F50301.jpg&w=3840&q=50)